Generic placeholder image

Current Drug Therapy

Author(s): Maria Aktsiali, Theodora Papachrysanthou , Ioannis Griveas, Christos Andriopoulos, Panagiotis Sitaras, Ioannis K. Triantafyllopoulos and George I. Lambrou*

DOI: 10.2174/1574885514666190802144629

DownloadDownload PDF Flyer Cite As
Treatment with Cinacalcet in Hemodialysis Patients with Severe Secondary Hyperparathyroidism, Influences Bone Mineral Metabolism and Anemia Parameters

Page: [249 - 263] Pages: 15

  • * (Excluding Mailing and Handling)

Abstract

Background: Due to the premium rate of Chronic Kidney Disease, we have increased our knowledge with respect to diagnosis and treatment of Bone Mineral Disease (BMD) in End- Stage Renal Disease (ESRD). Currently, various treatment options are available. The medication used for Secondary Hyper-Parathyroidism gives promising results in the regulation of Ca, P and Parathormone levels, improving the quality of life. The aim of the present study was to investigate the relation of cinacalcet administration to not only parathormone, Ca and P but also to anemia parameters such as hematocrit and hemoglobin.

Materials and Methods: A retrospective observational study was conducted in a Chronic Hemodialysis Unit. One-hundred ESRD patients were recruited for twenty-four months and were evaluated on a monthly rate. Biochemical parameters were related to medication prescribed and the prognostic value was estimated. Cinacalcet was administered to 43 out of 100 patients in a dose of 30-120 mg.

Results: Significant differences were observed in PTH, Ca and P levels with respect to Cinacalcet administration. Ca levels appeared to be higher at 30mg as compared to 60mg cinacalcet. Furthermore, a decreasing age-dependent pattern was observed with respect to cinacalcet dosage. A positive correlation was observed between Dry Weight (DW) and cinacalcet dose. Finally, a positive correlation between Hematocrit and Hemoglobin and cinacalcet was manifested.

Conclusions: Cinacalcet, is a potential cardiovascular and bone protective agent, which is approved for use in ESRD patients to assist SHPT. A novel information was obtained from this study, regarding the improvement of the control of anemia.

Keywords: Cinacalcet, renal disease, dialysis, bone mineral metabolism, anemia, hemoglobin.

Graphical Abstract

[1]
Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, et al. COSMOS group. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transplant 2015; 30(9): 1542-51.
[http://dx.doi.org/10.1093/ndt/gfv099] [PMID: 25920921]
[2]
Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann Intern Med 2018; 168(6): 422-30.
[http://dx.doi.org/10.7326/M17-2640] [PMID: 29459980]
[3]
Ribeiro C, Penido MG, Guimarães MM, et al. Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism. World J Nephrol 2016; 5(5): 437-47.
[http://dx.doi.org/10.5527/wjn.v5.i5.437] [PMID: 27648407]
[4]
Pérez-Hernández N, Aptilon-Duque G, Blachman-Braun R, et al. Vascular Calcification: Current Genetics Underlying This Complex Phenomenon. Chin Med J (Engl) 2017; 130(9): 1113-21.
[http://dx.doi.org/10.4103/0366-6999.204931] [PMID: 28469108]
[5]
Sprague SM, Evenepoel P, Curzi MP, et al. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 2009; 4(9): 1465-76.
[http://dx.doi.org/10.2215/CJN.06141108] [PMID: 19696213]
[6]
Barman Balfour JA, Scott LJ. Cinacalcet hydrochloride. Drugs 2005; 65(2): 271-81.
[http://dx.doi.org/10.2165/00003495-200565020-00007] [PMID: 15631545]
[7]
Yokoyama K, Ohkido I, Ishida M, et al. Cinacalcet for hemodialyzed patients with or without a high PTH level to control serum calcium and phosphorus: ECO (evaluation of cinacalcet HCl outcome) study. Clin Nephrol 2012; 78(2): 87-92.
[http://dx.doi.org/10.5414/CN107285] [PMID: 22790452]
[8]
Moe SM, Abdalla S, Chertow GM, et al. Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial investigators. Effects of Cinacalcet on fracture events in patients receiving hemodialysis: the evolve trial. J Am Soc Nephrol 2015; 26(6): 1466-75.
[http://dx.doi.org/10.1681/ASN.2014040414] [PMID: 25505257]
[9]
Evans M, Methven S, Gasparini A, et al. Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Sci Rep 2018; 8(1): 2103.
[http://dx.doi.org/10.1038/s41598-018-20552-5] [PMID: 29391567]
[10]
Torun D, Yildiz I, Micozkadioglu H, Nursal GN, Yigit F, Ozelsancak R. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism. Saudi J Kidney Dis Transpl 2016; 27(1): 15-22.
[http://dx.doi.org/10.4103/1319-2442.174053] [PMID: 26787561]
[11]
Fusaro M, D’Angelo A, Naso A, et al. Treatment with calcimimetic (cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report. Ren Fail 2011; 33(7): 732-5.
[http://dx.doi.org/10.3109/0886022X.2011.589937] [PMID: 21671845]
[12]
Mpio I, Boumendjel N, Karaaslan H, et al. Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study. Nephrol Ther 2011; 7(4): 229-36.
[http://dx.doi.org/10.1016/j.nephro.2011.01.008] [PMID: 21353659]
[13]
Foundation NK. National Kidney Foundation. National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 2015; 66(5): 884-930.
[http://dx.doi.org/10.1053/j.ajkd.2015.07.015] [PMID: 26498416]
[14]
National Kidney Foundation. 2015 update. Am J Kidney Dis 2015; 66(5): 884-930.
[http://dx.doi.org/10.1053/j.ajkd.2015.07.015] [PMID: 26498416]
[15]
Floege J, Amann K. Primary glomerulonephritides. Lancet 2016; 387(10032): 2036-48.
[http://dx.doi.org/10.1016/S0140-6736(16)00272-5] [PMID: 26921911]
[16]
Sharma M, Doley P, Das HJ. Etiological profile of chronic kidney disease: A single-center retrospective hospital-based study. Saudi J Kidney Dis Transpl 2018; 29(2): 409-13.
[http://dx.doi.org/10.4103/1319-2442.229297] [PMID: 29657211]
[17]
Kim KS, Park SW, Cho YW, Kim SK. Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus. Diabetes Metab J 2018; 42(3): 224-32.
[http://dx.doi.org/10.4093/dmj.2017.0065] [PMID: 29885112]
[18]
Grzegorzewska AE, Młot-Michalska M. Predictors of bone mineral density in dialyzed and non-dialyzed patients with chronic kidney disease. Adv Perit Dial 2010; 26: 116-24.
[PMID: 21348393]
[19]
Parfrey PS, Chertow GM, Block GA, et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab 2013; 98(12): 4834-44.
[http://dx.doi.org/10.1210/jc.2013-2975] [PMID: 24108314]
[20]
Ohashi Y, Sakai K, Hase H, Joki N. Dry weight targeting: the art and science of conventional hemodialysis. Semin Dial 2018; 31(6): 551-6.
[http://dx.doi.org/10.1111/sdi.12721] [PMID: 29876972]
[21]
Saint-Remy A, Krzesinski JM. Optimal blood pressure level and best measurement procedure in hemodialysis patients. Vasc Health Risk Manag 2005; 1(3): 235-44.
[PMID: 17319109]
[22]
Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5(7): 1255-60.
[http://dx.doi.org/10.2215/CJN.01760210] [PMID: 20507951]
[23]
Oliveira TS, Valente AT, Caetano CG, Garagarza CA. Nutritional parameters as mortality predictors in haemodialysis: Differences between genders. J Ren Care 2017; 43(2): 83-91.
[http://dx.doi.org/10.1111/jorc.12201] [PMID: 28417563]
[24]
Ahbap E, Sakaci T, Kara E, et al. Relationship between relative interdialytic weight gain and serum leptin levels, nutrition, and inflammation in chronic hemodialysis patients. Clin Nephrol 2015; 83(3): 154-60.
[http://dx.doi.org/10.5414/CN108450] [PMID: 25685870]
[25]
Çelik G, Oc B, Kara I, Yılmaz M, Yuceaktas A, Apiliogullari S. Comparison of nutritional parameters among adult and elderly hemodialysis patients. Int J Med Sci 2011; 8(7): 628-34.
[http://dx.doi.org/10.7150/ijms.8.628] [PMID: 22022216]
[26]
Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis 2018; 71(3): 423-35.
[http://dx.doi.org/10.1053/j.ajkd.2017.09.026] [PMID: 29336855]
[27]
Ruderman I, Smith ER, Toussaint ND, Hewitson TD, Holt SG. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism. BMC Nephrol 2018; 19(1): 113.
[http://dx.doi.org/10.1186/s12882-018-0910-9] [PMID: 29764395]
[28]
Bellasi A, Mangano M, Galassi A, Cozzolino M. [CKD-MBD, cardiovascular involvement and prognosis] G Ital Nefrol 2017; 34(Suppl. 69): 150-61.
[PMID: 28682036]
[29]
Klejna K, Naumnik B, Gasowska K, Myśliwiec M. OPG/RANK/RANKL signaling system and its significance in nephrology. Folia Histochem Cytobiol 2009; 47(2): 199-206.
[http://dx.doi.org/10.2478/v10042-009-0035-x] [PMID: 19995704]
[30]
Duplancic D, Cesarik M, Poljak NK, et al. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. Clin Interv Aging 2013; 8: 149-56.
[PMID: 23430986]
[31]
Panizo S, Barrio-Vázquez S, Naves-Díaz M, et al. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Nephrol Dial Transplant 2013; 28(11): 2735-44.
[http://dx.doi.org/10.1093/ndt/gft268] [PMID: 24013683]
[32]
Xu X, Chen G, Li Y, Wang J, Yin J, Ren L. Enhanced dissolution and oral bioavailbility of cinacalcet hydrochlorde nanocrystals with no food effect. Nanotechnology 2019; 30(5)055102
[http://dx.doi.org/10.1088/1361-6528/aaef46] [PMID: 30511665]
[33]
Abidin MNZ, Goh PS, Ismail AF, et al. Highly adsorptive oxidized starch nanoparticles for efficient urea removal. Carbohydr Polym 2018; 201: 257-63.
[http://dx.doi.org/10.1016/j.carbpol.2018.08.069] [PMID: 30241818]
[34]
Chen HC, Cheng CY, Lin HC, et al. Multifunctions of excited gold nanoparticles decorated artificial kidney with efficient hemodialysis and therapeutic potential. ACS Appl Mater Interfaces 2016; 8(30): 19691-700.
[http://dx.doi.org/10.1021/acsami.6b05905] [PMID: 27390874]
[35]
Chen HC, Lin HC, Chen HH, et al. Innovative strategy with potential to increase hemodialysis efficiency and safety. Sci Rep 2014; 4: 4425.
[http://dx.doi.org/10.1038/srep04425] [PMID: 24651843]
[36]
Devuyst O, Schumann A. Peritoneal dialysis: nanoparticles have entered the game. Perit Dial Int 2015; 35(3): 240.
[http://dx.doi.org/10.3747/pdi.2015.00075] [PMID: 26015416]
[37]
Stamopoulos D, Manios E, Gogola V, et al. Bare and protein-conjugated Fe(3)O(4) ferromagnetic nanoparticles for utilization in magnetically assisted hemodialysis: biocompatibility with human blood cells. Nanotechnology 2008; 19(50)505101
[http://dx.doi.org/10.1088/0957-4484/19/50/505101] [PMID: 19942758]
[38]
Farokhi M, Mottaghitalab F, Shokrgozar MA, Ou KL, Mao C, Hosseinkhani H. Importance of dual delivery systems for bone tissue engineering. J Control Release 2016; 225: 152-69.
[http://dx.doi.org/10.1016/j.jconrel.2016.01.033] [PMID: 26805518]
[39]
He C, Shi ZQ, Cheng C, et al. Graphene oxide and sulfonated polyanion co-doped hydrogel films for dual-layered membranes with superior hemocompatibility and antibacterial activity. Biomater Sci 2016; 4(10): 1431-40.
[http://dx.doi.org/10.1039/C6BM00494F] [PMID: 27526645]
[40]
Ou KL, Chu JS, Hosseinkhani H, Chiou JF, Yu CH. Biomedical nanostructured coating for minimally invasive surgery devices applications: characterization, cell cytotoxicity evaluation and an animal study in rat. Surg Endosc 2014; 28(7): 2174-88.
[http://dx.doi.org/10.1007/s00464-014-3450-9] [PMID: 24619328]
[41]
Sharifzadeh G, Hosseinkhani H. Biomolecule-responsive hydrogels in medicine. Adv Healthc Mater 2017; 6(24): 65-86.
[http://dx.doi.org/10.1002/adhm.201700801] [PMID: 29057617]
[42]
Ou KL, Hosseinkhani H. Development of 3D in vitro technology for medical applications. Int J Mol Sci 2014; 15(10): 17938-62.
[http://dx.doi.org/10.3390/ijms151017938] [PMID: 25299693]
[43]
Huang C-F, Chiang H-J, Lin H-J, et al. Comparison of cell response and surface characteristics on titanium implant with SLA and SLAffinity functionalization. J Electrochem Soc 2014; 161(3): G15-20.
[http://dx.doi.org/10.1149/2.084403jes]
[44]
Toosi S, Naderi-Meshkin H, Kalalinia F, et al. Long bone mesenchymal stem cells (Lb-MSCs): clinically reliable cells for osteo-diseases. Cell Tissue Bank 2017; 18(4): 489-500.
[http://dx.doi.org/10.1007/s10561-017-9652-3] [PMID: 28815364]